• Je něco špatně v tomto záznamu ?

Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro

H. Kostrhunova, O. Vrana, T. Suchankova, D. Gibson, J. Kasparkova, V. Brabec

. 2010 ; 23 (11) : 1833-1842. [pub] 20101012

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12026736

cis-Amminedichlorido(cyclohexylamine)platinum(II) (JM118) is an antitumor Pt(II) analogue of cisplatin exhibiting considerably higher activity than cisplatin in human tumor cells. JM118 is also the major metabolite of the first orally administered Pt(IV) drug satraplatin. In an effort to design improved platinum antitumor agents, it is important to elucidate the biochemical factors that affect the cytotoxic properties of existing platinum drugs. Since DNA is considered the major pharmacological target of platinum drugs, the objective in the present work was to understand more fully the DNA binding mode of antitumor JM118. We examined the rate of aquation of the first chloride of bifunctional JM118 and found that it was considerably lower than that of cisplatin; consequently, the rate of the reaction of JM118 with DNA was lower compared to cisplatin. The influence of global modification by JM118 and its major site-specific adducts on DNA conformation by biochemical methods was investigated as well. While examination of the global modification revealed in several cases no substantial differences in the lesions induced by JM118 and cisplatin, DNA bending due to the 1,2-GG intrastrand adduct of JM118 was lower than that of cisplatin. The bending angles afforded by the adducts of JM118 were only slightly affected by the orientation of the cyclohexylamine ligand toward the 3' or 5' direction of the duplex. We also used in vitro assays that make it possible to monitor DNA repair synthesis by cell-free extracts and DNA-protein cross-linking to probe properties of DNA adducts of JM118. These results showed a higher DNA-protein cross-linking efficiency of JM118 and a less efficient removal from DNA of the adducts of JM118 in comparison with cisplatin. Thus, the results of the present work provide additional evidence that DNA binding of JM118 is in several aspects different from that of conventional cisplatin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026736
003      
CZ-PrNML
005      
20160322105533.0
007      
ta
008      
120816s2010 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1021/tx1002904 $2 doi
035    __
$a (PubMed)20939593
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kostrhunová, Hana. $7 _AN047101 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
245    10
$a Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro / $c H. Kostrhunova, O. Vrana, T. Suchankova, D. Gibson, J. Kasparkova, V. Brabec
520    9_
$a cis-Amminedichlorido(cyclohexylamine)platinum(II) (JM118) is an antitumor Pt(II) analogue of cisplatin exhibiting considerably higher activity than cisplatin in human tumor cells. JM118 is also the major metabolite of the first orally administered Pt(IV) drug satraplatin. In an effort to design improved platinum antitumor agents, it is important to elucidate the biochemical factors that affect the cytotoxic properties of existing platinum drugs. Since DNA is considered the major pharmacological target of platinum drugs, the objective in the present work was to understand more fully the DNA binding mode of antitumor JM118. We examined the rate of aquation of the first chloride of bifunctional JM118 and found that it was considerably lower than that of cisplatin; consequently, the rate of the reaction of JM118 with DNA was lower compared to cisplatin. The influence of global modification by JM118 and its major site-specific adducts on DNA conformation by biochemical methods was investigated as well. While examination of the global modification revealed in several cases no substantial differences in the lesions induced by JM118 and cisplatin, DNA bending due to the 1,2-GG intrastrand adduct of JM118 was lower than that of cisplatin. The bending angles afforded by the adducts of JM118 were only slightly affected by the orientation of the cyclohexylamine ligand toward the 3' or 5' direction of the duplex. We also used in vitro assays that make it possible to monitor DNA repair synthesis by cell-free extracts and DNA-protein cross-linking to probe properties of DNA adducts of JM118. These results showed a higher DNA-protein cross-linking efficiency of JM118 and a less efficient removal from DNA of the adducts of JM118 in comparison with cisplatin. Thus, the results of the present work provide additional evidence that DNA binding of JM118 is in several aspects different from that of conventional cisplatin.
650    _2
$a protinádorové látky $x chemie $x toxicita $7 D000970
650    _2
$a sekvence nukleotidů $7 D001483
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cirkulární dichroismus $7 D002942
650    _2
$a cisplatina $x chemie $x toxicita $7 D002945
650    _2
$a DNA $x chemie $7 D004247
650    _2
$a adukty DNA $x chemie $7 D018736
650    _2
$a oprava DNA $7 D004260
650    _2
$a lidé $7 D006801
650    _2
$a denaturace nukleových kyselin $7 D009691
650    _2
$a organoplatinové sloučeniny $x chemie $x toxicita $7 D009944
650    _2
$a tranzitní teplota $7 D044366
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vrána, Oldřich, $d 1956- $7 xx0097595 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
700    1_
$a Suchánková, Tereza, $d 1983- $7 mub2011617906 $u Department of Experimental Physics, Faculty of Sciences, Palacky University, 17. listopadu 12, 77146 Olomouc, Czech Republic
700    1_
$a Gibson, Dan $u Department of Medicinal Chemistry and Natural Products, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
700    1_
$a Kašpárková, Jana, $d 1969- $7 xx0068609 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
700    1_
$a Brabec, Viktor, $d 1944- $7 jo20010087133 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
773    0_
$w MED00002106 $t Chemical research in toxicology $x 1520-5010 $g Roč. 23, č. 11 (2010), s. 1833-1842
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20939593 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160322105602 $b ABA008
999    __
$a ok $b bmc $g 948778 $s 784082
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 23 $c 11 $d 1833-1842 $e 20101012 $i 1520-5010 $m Chemical research in toxicology $n Chem Res Toxicol $x MED00002106
LZP    __
$b NLK122 $a Pubmed-20120816/11/01

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...